Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc to Discuss SITC Clinical Data Updates Transcript

Nov 13, 2021 / 10:30PM GMT
Operator

Good day, thank you for standing by, and welcome to the Iovance SITC Update Call. (Operator Instructions)

I would now like to turn the conference over to your host, Ms. Sara Pellegrino, Vice President, Investor and Public Relations of Iovance Biotherapeutics. Please go ahead, ma'am.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon, and thank you for joining our conference call to discuss the clinical data updates for Iovance TIL cell therapy in multiple solid tumors during SITC 2021. For today's agenda, our Interim President and CEO, Fred Vogt will do a brief introduction; Dr. Friedrich Finckenstein, our Chief Medical Officer, will highlight the key takeaways for each data set in relation to our TIL development strategy. The highlight of today's call will be clinical data updates for Iovance TIL in metastatic non-small cell lung cancer and Iovance TIL in combination with pembrolizumab in early-line cervical cancer, melanoma and head and neck cancer.

We are fortunate to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot